HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs

Recruiting now · Not applicable

Conditions studied: Degenerative Disc Disease (DDD)

In brief

A multi-center, prospective, dual arm, randomized, controlled pivotal study to evaluate the safety and effectiveness of the ReGelTec HYDRAFIL™ System.

Key facts

Study ID

NCT06011551

Run by

ReGelTec, Inc.

People needed

225

Starts

2025-01-13

Expected to finish

2028-12-31

Last updated by the study team

2026-07-30

Who can join

Age: 22 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female subjects aged 22 to 85 years, inclusive
• Subjects presenting with LBP greater than leg pain and symptoms of DDD of the lumbar region (L1- S1) of at least six (6) months duration
• Presence of one (1) or two (2) symptomatic disc(s) (i.e., only 1-level or 2-levels may be treated during the study) as determined by Discography
• Symptomatic disc(s) exhibiting Grade 4 to 8 degeneration on the modified Pfirrmann scale as determined by MRI
• Failure to have their symptoms resolve or reduce following at least six (6) months of conservative care (as defined in the body of the protocol)
• Psychosocially, mentally and physically able and willing to fully comply with this protocol including adhering to follow-up schedule and requirements and filling out forms
• English fluency
• Signed informed consent

You may not qualify if…

• Active systemic or local infection
• Any skin disease or inadequate tissue coverage at the site of the proposed injection
• Annular tear or defect that shows free contrast extravasation into the epidural space during or after Discography
• Presence of more than two (2) symptomatic discs presenting with pain confirmed during Discography
• Presence of extruded or sequestered disc herniation (i.e., disc extrusions or sequestrations) at the symptomatic level(s) or on adjacent levels
• Presence of wide annular fissures confluent with large disc protrusions at the symptomatic level(s)
• Epidural steroid injection, intradiscal injection, trigger point injection, facet or medial branch block within 60 days of randomization
• Opioid medication usage >60 MME (morphine milligram equivalent)/day or increase in opioid use within 60 days of randomization
• Evidence of Modic type 3 changes at the symptomatic level(s) or on adjacent levels
• Subjects presenting with nerve pain following a dermatomal distribution and that correlates with nerve compression on imaging where lower limb pain is greater than back pain or by history within the past six (6) months. Note: somatic referred pain is allowed
• Evidence of neurogenic claudication due to spinal stenosis
• Subjects having had any prior lumbar spine surgery (instrumented or non-instrumented) except: a. A non-instrumented procedure not at the symptomatic or adjacent levels (i.e., discectomy, laminectomy, MILD procedure) is not exclusionary if the procedure was completed at least one (1) year or greater from randomization with complete resolution of treated symptoms and no recurrence
• History of vertebral fractures in the lumbar spine
• Evidence of severe compression of cauda equina
• Evidence of spinal segmental instability (spondylolysis or spondylolisthesis: Grade >1), severe spinal canal stenosis, isthmus pathology, or scoliosis [Cobb angle >20 at the index level(s)]
• Subjects with arachnoiditis
• Subjects who are prisoners or wards of courts
• Subjects involved in active litigation including worker's compensation cases
• Subjects on chronic anticoagulation due to a bleeding disorder and unable to safely stop anticoagulants, or has taken anticoagulants within three (3) days prior to procedure
• Subjects with LBP of non-spinal or unknown etiology
• Subjects who have a history (in the last five (5) years) of substance abuse or chemical dependency (pharmaceuticals, illicit drugs, alcohol) or are current abusers (using definition criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-V))
• Subjects who have major psychiatric disorders, such as major depression, bipolar disorder and schizophrenia, as defined by the DSM-V
• If female, subjects who are pregnant or are trying to become pregnant during the course of the trial (due to risks of additional radiation exposures)
• Failure to understand informed consent or inability or unwillingness to adhere to the study follow-up visit schedule or other protocol requirements
• Subjects who have participated in any other clinical study within the last three (3) months that, in the opinion of the investigator, could bias the results of the HYDRAFIL-D study, or subjects that are actively participating in any other clinical study, or have planned participation in any other clinical study during the course of this trial. Note: subjects must agree they will not participate in any other clinical study during the course of this trial

Where it is running

• Alabama Clinical Therapeutics — Birmingham, Alabama, United States (enrolling)
• Source Healthcare — Santa Monica, California, United States (enrolling)
• Boomerang Healthcare (IPM Medical Group) — Walnut Creek, California, United States (enrolling)
• DBPS Research (The Denver Spine & Pain Institute) — Greenwood Village, Colorado, United States (enrolling)
• The Orthopaedic Institute — Gainesville, Florida, United States (enrolling)
• Southwest Florida Pain Center — Port Charlotte, Florida, United States (enrolling)
• NRSA Group (Florida Spine & Pain Specialists) — Riverview, Florida, United States (enrolling)
• Tenet Florida Physician Services II (Cantor Spine Center at The Paley Orthopedic and Spine Institute) — West Palm Beach, Florida, United States (enrolling)
• Horizon Clinical Research (Southern Pain and Spine) — Jasper, Georgia, United States (enrolling)
• Neuroscience Research Center, LLC — Overland Park, Kansas, United States (enrolling)
• Spine Institute of Louisiana (The Spine Network) — Shreveport, Louisiana, United States (enrolling)
• Clinical Investigations — Edmond, Oklahoma, United States (enrolling)
• Precision Spine Care — Tyler, Texas, United States (enrolling)
• Virginia iSpine Physicians — Richmond, Virginia, United States (enrolling)
• Beam Research (Beam Radiology) — Calgary, Alberta, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.